Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStein, A.en
dc.contributor.authorBottino, D.en
dc.contributor.authorModur, V.en
dc.contributor.authorBranford, S.en
dc.contributor.authorKaeda, J.en
dc.contributor.authorGoldman, J.en
dc.contributor.authorHughes, T.en
dc.contributor.authorRadich, J.en
dc.contributor.authorHochhaus, A.en
dc.identifier.citationClinical Cancer Research, 2011; 17(21):6812-6821en
dc.description.abstract<h4>Purpose</h4>Imatinib induces a durable response in most patients with Philadelphia chromosome-positive chronic myeloid leukemia, but it is currently unclear whether imatinib reduces the leukemic stem cell (LSC) burden, which may be an important step toward enabling safe discontinuation of therapy. In this article, we use mathematical models of BCR-ABL levels to make inferences on the dynamics of LSCs.<h4>Experimental design</h4>Patients with at least 1 BCR-ABL transcript measurement on imatinib were included (N = 477). Maximum likelihood methods were used to test 3 potential hypotheses of the dynamics of BCR-ABL transcripts on imatinib therapy: (i) monoexponential, in which there is little, if any, decline in BCR-ABL transcripts; (ii) biexponential, in which patients have a rapid initial decrease in BCR-ABL transcripts followed by a more gradual response; and (iii) triexponential, in which patients first exhibit a biphasic decline but then have a third phase when BCR-ABL transcripts increase rapidly.<h4>Results</h4>We found that most patients treated with imatinib exhibit a biphasic decrease in BCR-ABL transcript levels, with a rapid decrease during the first few months of treatment, followed by a more gradual decrease that often continues over many years.<h4>Conclusions</h4>We show that the only hypothesis consistent with current data on progenitor cell turnover and with the long-term, gradual decrease in the BCR-ABL levels seen in most patients is that these patients exhibit a continual, gradual reduction of the LSCs. This observation may explain the ability to discontinue imatinib therapy without relapse in some cases.en
dc.description.statementofresponsibilityAndrew M. Stein, Dean Bottino, Vijay Modur, Susan Branford, Jaspal Kaeda, John M. Goldman, Timothy P. Hughes, Jerald P. Radich, and Andreas Hochhausen
dc.publisherAmer Assoc Cancer Researchen
dc.rights©2011 American Association for Cancer Research.en
dc.subjectHumans; Benzamides; Piperazines; Pyrimidines; Fusion Proteins, bcr-abl; RNA, Messenger; Antineoplastic Agents; Protein Kinase Inhibitors; Hematopoiesis; Protein-Tyrosine Kinases; Neoplastic Stem Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Real-Time Polymerase Chain Reaction; Imatinib Mesylateen
dc.titleBCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib teatmenten
dc.typeJournal articleen
dc.identifier.orcidBranford, S. [0000-0002-1964-3626]en
dc.identifier.orcidHughes, T. [0000-0002-0910-3730]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.